SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SOFI is trending as investors anticipate upcoming earnings, with some speculating about a potential leak and others pointing to favorable macroeconomic conditions like potential rate cuts. The community is weighing the possibility of a post-earnings short squeeze against concerns of overvaluation and a potential sell-off. Some see SOFI as a long-term growth play, drawing comparisons to other high-growth tech companies and anticipating future S&P 500 inclusion.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending due to a significant after-hours drop following the announcement of a $1 billion convertible note offering, despite recent strong earnings. The community is debating whether this offering signals growth financing or potential dilution, with some viewing it as a buying opportunity while others express concern about the short-term impact. Discussion also involves the company's AI data center plans and potential ERCOT approval.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

DGXX is trending as investors focus on the company's potential in AI and data centers, with community members pointing to its advantageous position in the sector, zero debt, and increasing volume. Conversations revolve around potential tenant news and the possibility of a significant run, fueled by growing interest from institutional investors. Some traders note its potential for significant growth given recent partnerships and expansion plans.

ETHZilla Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZ is trending due to discussions around a recent reverse stock split and its potential impact on the company's valuation. The community is actively debating the implications of the split, a stock buyback program, and the company's Ethereum holdings. Some traders are pointing to potential upside due to the buyback, while others express concern about dilution and management strategy.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following news of its entrance into the AI accelerator chip market, directly challenging Nvidia and AMD; this includes a partnership with Saudi Arabia. Community members are actively debating whether Qualcomm can truly compete in the AI hardware space, while some highlight its attractive valuation compared to competitors.  Discussions also involve potential collaborations and impacts on related stocks.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is trending amid discussions surrounding its pending acquisition by CoreWeave (CRWV), with a shareholder vote approaching. Community talking points include whether the all-stock deal undervalues CORZ, especially given its infrastructure and potential in the AI data center space, and what the potential implications of a 'yes' or 'no' vote will be for both companies.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies ($AVR) is trending following the enrollment of the first patients in its global pivotal trial for the DurAVR Transcatheter Heart Valve, with the procedures performed in Denmark. Community members are discussing the company's potential, recent stock offerings, and potential price targets. Some traders are also pointing to technical indicators like cup and handle patterns while others mention institutional support.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors weigh the impact of restructuring and potential dividend cuts ahead of earnings. The community is actively discussing insider sentiment, with some questioning the company's leadership and others seeing a long-term value play due to its high dividend yield. Broader market concerns and upcoming earnings are fueling uncertainty around the stock's near-term direction.

Waste Management, Inc. is a holding company, which engages in the provision of waste management environmental services. It operates through the following segments: Collection and Disposal-East Tier (East Tier), Collection and Disposal-West Tier (West Tier), Recycling Processing and Sales, WM Renewable Energy, and VM Healthcare Solutions. The East Tier segment includes the Eastern United States, the Great Lakes Region, and Canada. The West Tier segment refers to the upper Midwest region and British Columbia, Canada. The Recycling Processing and Sales segment focuses on the processing and sales of materials collected from residential, commercial, and industrial customers. The WM Renewable Energy segment develops, operates, and promotes projects for landfill gas use. The VM Healthcare Solutions segment relates to its primarily business to business company providing services that protect people and brands, promote health and well-being and safeguard the environment. The company was founded on September 30, 1987 and is headquartered in Houston, TX.

Waste Management, Inc.

Waste Management is trending due to a slight miss on Q3 earnings expectations despite solid revenue growth, prompting discussions about tax loss harvesting and long-term investment opportunities. While some investors express disappointment and consider it a tax write-off, others view the dip as a chance to buy into the defensive stock, highlighting its steady performance and essential service nature within the resilient waste management sector.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond ($BBBY) is trending as the familiar ticker returns, sparking speculation about a potential meme stock resurgence and comparisons to $GME. The community is actively discussing the company's blockchain ties through Tzero, and whether Ryan Cohen might be involved in a future play. Some traders are also closely watching earnings and the potential for a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio

Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.

A White House official reportedly said on Friday that countries with existing trade agreements with the U.S. would be exempt from the recently announced pharmaceutical tariffs.&nbsp;According to a Reuters report&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/news/reuters.com,2025:newsml_S0N3U402V:0-latest-drug-tariffs-don-t-apply-to-nations-with-trade-deals-white-house-says/">cited</a> by TradingView, when asked whether pharmaceutical tariffs would apply to trading partners such as the European Union and Japan, which already have trade deals, the official stated that the Trump administration would honor the 15% cap as part of those pacts. Other nations with U.S. trade deals include Vietnam, the U.K., Indonesia, and the Philippines. Major partners like India, Canada, and Mexico have yet to finalize&nbsp;an agreement.The clarification comes after President Donald Trump on Thursday announced a 100% tariff on imported, branded, and patented pharmaceutical drugs starting October 1. In his Truth Social&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/115267512131958759">post</a> announcing the tariffs, Trump only highlighted that an exception would be made for any company that is “IS BUILDING their Pharmaceutical Manufacturing Plant in America.” He explained that “is building” refers to “‘breaking ground’ and/or ‘under construction’.”In a note to investors on Friday morning, Jefferies analyst Akash Tewari described the new pharmaceutical tariffs as "a win for Pharma" and "a light at the end of the Trump tunnel," noting that several large-cap companies have already announced U.S. manufacturing projects. Tewari suggested the tariffs and the MFN pilot program may serve as a symbolic “on paper” win ahead of midterms, with limited material impact on pharmaceutical companies.The 100% tariff is higher than what Trump had indicated in August.&nbsp; He&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">stated</a> that tariffs would be increased over time, allowing companies sufficient time to build factories and relocate production. Trump had said he would start by charging a “small tariff” on pharmaceuticals and raise the rate over a year or more to 150% and even 250%.The&nbsp;<a href="https://stocktwits.com/symbol/IHE">iShares U.S. Pharmaceuticals ETF (IHE)</a> edged 1.3% higher in midday trade. On Stocktwits, retail sentiment around the ETF improved to ‘neutral’ from ‘bearish over the past day. Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> rose 0.86% with retail sentiment trending in ‘bullish’ territory as chatter rose to ‘high’ from ‘normal’ levels.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pce-report-core-inflation-holds-steady-at-2-9-in-august/chDViYeR3eE">PCE Report: Core Inflation Holds Steady At 2.9% In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report

According to a Reuters report cited by TradingView, a White House official stated that the Trump administration will honor the 15% pharmaceutical tariff cap for trade partners such as the EU and Japan, as outlined in existing agreements.

Equity

Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.     

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend. 

ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

White House Press Secretary Karoline Leavitt said on Thursday that President Donald Trump is set to send out letters to 17 pharmaceutical company CEOs in the U.S., including Eli Lilly (LLY), giving them 60 days to address the global pricing disparity of drugs.“Other nations have been free-loading on U.S. innovation for far too long, and it is time they pay their fair share,” said Leavitt, reading out one of the letters, addressed to Eli Lilly CEO David A. Ricks.<a href="http://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> dipped more than 1% in afternoon trade after the news broke. On Stocktwits, retail sentiment around the pharmaceutical giant remained in ‘bullish’ territory over the past day.Other pharma stocks also took a hit. Moderna (MRNA) extended its downtrend, dipping nearly 7%, AstraZeneca (AZN) slipped more than 3% and Pfizer (PFE) was down over 1%.&nbsp;The warning comes after Trump signed an executive order delivering ‘most favored nation’ prescription drug pricing for U.S. patients in May.The letter alleges that most of the proposals that the Trump administration has received to resolve the issue of drug pricing promised “more of the same, shifting blame, and requesting policy changes that would result in billions of dollars in handouts to the industry.”It outlines that drug makers have 60 days to achieve the following goals:- Extend the ‘most favored nation’ pricing to Medicaid- Guarantee ‘most favored nation’ pricing for newly launched drugs- Return increased revenues abroad to American patients and taxpayers- Provided for direct purchasing at ‘most favored nation’ pricing“But if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,” warned the letter, adding that the Trump administration, U.S. Health Secretary Robert Kennedy Jr. and Centers for Medicare and Medicaid Services (CMS) administrator Mehmet Oz stand ready to implement these terms.&nbsp;According to the letter, the companies have till September 29 to comply.&nbsp;The VanEck Pharmaceutical ETF (PPH) dropped more than 2%, while the iShares U.S. Pharmaceutics ETF (IHE) edged 0.8% lower.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sec-chair-unveils-project-crypto-to-back-trump-push-for-us-crypto-dominance/choLhyMRdG4">SEC Chair Unveils ‘Project Crypto’ To Back Trump’s Push For US Crypto Dominance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Donald Trump gestures during a meeting with British Prime Minister Keir Starmer (not pictured) on July 28, 2025 in Turnberry, Scotland. (Photo by Christopher Furlong/Getty Images)

Trump To Issue 60-Day Warning Letters To Drugmakers Over Pricing 

The U.S. President is expected to send out these letters through his social media platform, Truth Social.

AstraZeneca stock climbed nearly 3% in Tuesday’s early premarket session after the Cambridge, U.K.-based biopharma giant reported a beat for the second quarter of the fiscal year 2025 and reiterated its full-year outlook.The company reported second-quarter core earnings per share (EPS) of $1.58, a 27% increase year over year (YoY), and revenue of $14.46 billion, representing a 12% rise.&nbsp;The results exceeded the company's compiled consensus estimates of $2.16 billion and $14.46 billion, respectively, Reuters reported.On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/AZN">AstraZeneca stock</a> stayed ‘bullish’ (57/100) early Tuesday, and the 24-hour message volume was also at ‘high levels.<figure class="image"><img style="aspect-ratio:618/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_29_at_5_24_42_AM_png_b578c580c0.webp" alt="Screenshot 2025-07-29 at 5.24.42 AM.png" width="618" height="58"><figcaption>AZN stock sentiment and message volume as of 5:20 a.m. ET, July 29 | source: Stocktwits</figcaption></figure>A bullish watcher lauded the company for an “excellent earnings report.”<stembedurl>https://stocktwits.com/Uncle_Baby_Billy/message/622814998</stembedurl>Product sales rose 11% to $13.80 billion, or 95.4% of the total revenue, thanks to double-digit growth in Oncology and biopharmaceutical sales.&nbsp;Its oncology franchise fetched revenue of $6.32 billion, accounting for 44% of the total revenue and witnessing 18% growth. Imfinzi and Tagrisso sales jumped 10% and 13%, respectively.Respiratory and Immunology Revenue climbed 13% to $2.15 billion, or 15% of the total.The company said all the major geographical regions saw YoY revenue growth. The U.S., which accounted for 43% of the company's total revenue, experienced 13% growth.&nbsp;AstraZeneca CEO Pascal Soriot said, “Our strong momentum in revenue growth continued through the first half of the year … with 12 positive key Phase III trial readouts including for baxdrostat, gefurulimab, and Tagrisso in just the past few weeks.”Looking ahead, AstraZeneca reiterated its revenue and core EPS growth guidance for the fiscal year 2025, expecting high-single-digit constant currency revenue growth and low double-digit core EPS growth.Soriot noted that the company has pledged $50 billion to expand in the U.S., its key market, amid President Donald Trump’s push to bring manufacturing back onshore. The company is making its biggest-ever investment in a manufacturing facility in Virginia.He reiterated the company’s long-term goal of hitting $80 billion in revenue by 2030.AstraZeneca’s U.S.-listed shares have gained about 4.6% this year, underperforming the broader market.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stellantis-stock-slides-premarket-as-auto-giant-reinstated-guidance-leaves-investors-unimpressed/cho9oJ1R5Ug">Stellantis Stock Slides Premarket As Auto Giant’s Reinstated Guidance Leaves Investors Unimpressed</a>

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers

Product sales rose 11% to $13.80 billion, or 95.4% of the total revenue, thanks to double-digit growth in Oncology and biopharmaceutical sales.

Merck (MRK) announced on Monday that the Canadian regulator, Health Canada, has granted approval for its cancer drug Keytruda in combination with chemoradiotherapy (CRT) for the treatment of advanced-stage cervical cancer.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRK">Merck</a> trended in the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:1366/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_21_at_11_37_27_AM_png_3a0152bdf1.webp" alt="MRK's Sentiment Meter and Message Volume as of 11:37 a.m. ET on July 21, 2025 | Source: Stocktwits" width="1366" height="128"><figcaption>MRK's Sentiment Meter and Message Volume as of 11:37 a.m. ET on July 21, 2025 | Source: Stocktwits</figcaption></figure>The approval is <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newswire.ca/news-releases/health-canada-approves-keytruda-r-for-the-treatment-of-adult-patients-with-figo-2014-stage-iii-iva-cervical-cancer-in-combination-with-chemoradiotherapy-crt-1-810218043.html">based</a> on data from the late-stage trial. The data demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) in patients randomized to Keytruda in combination with CRT compared with patients randomized to placebo plus CRT. The trial enrolled 1,060 newly diagnosed patients.Cervical cancer forms in the cells lining the cervix, which is the lower part of the uterus. In 2024 alone, it was estimated that there were approximately 1,600 women diagnosed with cervical cancer and an estimated 400 deaths as a result of the disease, as per data from the Canadian Cancer Society.Keytruda was first approved in Canada in 2015 and is approved for the treatment of several cancers affecting the bladder, lung, breast, head and neck, and other areas.Meanwhile, Merck will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. Analysts on average expect the company to report earnings per share of $2.02, down from $2.28 per share in the corresponding quarter of 2024.Quarterly revenue is expected to be $15.86 billion, down from the $16.11 billion reported in the corresponding period of 2024.On Stocktwits, a user expressed optimism about the stock in light of the company’s restructuring plan, upcoming trial results, and solid financial position.<stembedurl>https://stocktwits.com/jjokerst/message/621710390</stembedurl>Another, however, sounded skeptical about the overall pharmaceutical and medical technology industry.<a href="https://stocktwits.com/YouOnlyLiveTwice/message/621754509">https://stocktwits.com/YouOnlyLiveTwice/message/621754509</a>Keytruda is Merck’s blockbuster cancer drug. In the three months through the end of March, Keytruda sales increased 4% to $7.2 billion, driven by a rise in global uptake in earlier-stage indications and continued strong demand worldwide.Through full year 2024, Keytruda total sales were $29.48 billion, accounting for about 46% of the company’s total sales.MRK stock is down 20% this year and approximately 37% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-sees-28-percent-slide-in-chatter-over-past-week/ch8kz4ZR5qy">Tesla Stock Sees 28% Slide In Retail Chatter Over Past Week Ahead Of Q2 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided

Keytruda was first approved in Canada in 2015 and is approved for the treatment of several cancers affecting the bladder, lung, breast, head and neck, and other areas. 

VanEck ETF Trust - VanEck Pharmaceutical ETF

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

PPH
VanEck Pharmaceutical ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PPH News

PPHVanEck Pharmaceutical ETF